Engineered CCL20 locked dimer polypeptide
The present invention provides a CCL20 locked dimer polypeptide, pharmaceutical compositions thereof, and methods of using said dimer in the treatment of psoriasis and psoriatic arthritis.
1. A method of treating psoriasis in a subject having or at risk of having psoriasis, the method comprising administering to the subject a therapeutically effective amount of a composition comprising a CCL20 locked dimer polypeptide to treat the psoriasis, wherein the CCL20 locked dimer comprises two monomers covalently linked together, wherein each monomer has an amino acid sequence comprising SEQ ID NO: 1.
2. The method of claim 1 , wherein the subject is a mammal.
3. The method of claim 1 , wherein the subject is a human.
4. The method of claim 1 , wherein administering the composition results in a reduction in skin inflammation and one or more symptoms of psoriasis.
5. A method of treating psoriatic arthritis in a subject having or at risk of having psoriatic arthritis, the method comprising administering to the subject a therapeutically effective amount of a composition comprising a CCL20 locked dimer polypeptide to treat the psoriatic arthritis, wherein the CCL20 locked dimer comprises two monomers each having an amino acid sequence comprising SEQ ID NO:1 covalently linked together.
6. The method of claim 5 , wherein the subject is a mammal.
7. The method of claim 5 , wherein the subject is a human.
8. A method of reducing joint inflammation in a subject having or suspected of having psoriatic arthritis, the method comprising administering to the subject a therapeutically effective amount of a composition comprising a CCL20 locked dimer polypeptide to reduce joint inflammation, wherein the CCL20 locked dimer comprises two monomers each having an amino acid sequence comprising SEQ ID NO:1 covalently linked together.
9. The method of claim 8 , wherein the subject is a mammal.
10. The method of claim 8 , wherein the subject is a human.